UNSPSC 51372021: Acetorphine hydrochloride

This classification denotes an analgesic agent C27H35NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60E212GZCG, chemically known as (.alpha.r,5.alpha.,7.alpha.)-4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-6,14-ethenomorphinan-7-methanol, but more generally known as acetorphine hydrochloride, which bears US NIH Compound Identifier 71587068. Most nations, for tariff and trade purposes, schedule acetorphine hydrochloride under HS 29391900 and SITC 54141.

As of Q4 2014, ACETORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC[C@](C)([C@H]1C[C@@]23C=C[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)OC(=O)C)O4)C)OC)O.CL.

UNSPSC 51372021 Acetorphine hydrochloride is a Commodity code that maps poorly to the state and local procurement activity recently tagged under it. The source shows no solicitations for acetorphine hydrochloride or other opioid pharmaceuticals by name. Instead, the three recent opportunities posted under this code involve naloxone procurement (a opioid antagonist), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and a request for information on direct-to-manufacturer prescription programs. The code's nominal scope—a specific controlled pharmaceutical ingredient—does not align with the actual work being solicited, which spans opioid-reversal supplies, broad-spectrum pharmaceutical distribution, and pharmacy benefit program design. This mismatch suggests either a cataloging error in the tagging system or that the code is being used as a catch-all for opioid-related or pharmaceutical procurement when a more precise Commodity or Class code does not exist in the taxonomy.

The issuing bodies include a Florida county health department (Seminole County), a state health agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). Recent activity spans three distinct procurement mechanisms: Seminole County's IFB for naloxone and drug deactivation systems (1,900 units annually, due July 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026, with contract start July 1, 2026). Geographic spread includes Florida, Texas, Minnesota, and Oregon. The absence of acetorphine-specific procurement and the prevalence of broader pharmaceutical distribution and opioid-antagonist work indicate that this code either requires reassignment or reflects institutional tagging inconsistency rather than a market segment with coherent recent demand.